MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
MYGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative. MYGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year MYGN was profitable.
In the past year MYGN has reported a negative cash flow from operations.
MYGN had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: MYGN reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of MYGN (-14.30%) is better than 83.96% of its industry peers.
With an excellent Return On Equity value of -20.96%, MYGN belongs to the best of the industry, outperforming 84.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.3% | ||
| ROE | -20.96% | ||
| ROIC | N/A |
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MYGN has a better Gross Margin (69.06%) than 83.24% of its industry peers.
In the last couple of years the Gross Margin of MYGN has declined.
MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYGN has been increased compared to 1 year ago.
MYGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MYGN is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.11 indicates that MYGN is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of MYGN (2.11) is better than 72.73% of its industry peers.
MYGN has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, MYGN is doing worse than 62.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.11 |
ROIC/WACCN/A
WACC10.4%
2.3 Liquidity
A Current Ratio of 1.96 indicates that MYGN should not have too much problems paying its short term obligations.
The Current ratio of MYGN (1.96) is worse than 76.47% of its industry peers.
MYGN has a Quick Ratio of 1.78. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
MYGN has a worse Quick ratio (1.78) than 77.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
MYGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 131.82%, which is quite impressive.
The Revenue has grown by 12.15% in the past year. This is quite good.
MYGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.25% yearly.
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)12.15%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Sales Q2Q%11.15%
3.2 Future
Based on estimates for the next years, MYGN will show a very strong growth in Earnings Per Share. The EPS will grow by 33.08% on average per year.
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 7.14% on average per year.
EPS Next Y139.45%
EPS Next 2Y70.34%
EPS Next 3Y56.46%
EPS Next 5Y33.08%
Revenue Next Year11.9%
Revenue Next 2Y9.8%
Revenue Next 3Y9.78%
Revenue Next 5Y7.14%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 109.96, which means the current valuation is very expensive for MYGN.
93.05% of the companies in the same industry are more expensive than MYGN, based on the Price/Earnings ratio.
MYGN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.65.
The Price/Forward Earnings ratio is 60.99, which means the current valuation is very expensive for MYGN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MYGN indicates a rather cheap valuation: MYGN is cheaper than 92.16% of the companies listed in the same industry.
MYGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 109.96 | ||
| Fwd PE | 60.99 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MYGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MYGN's earnings are expected to grow with 56.46% in the coming years.
PEG (NY)0.79
PEG (5Y)N/A
EPS Next 2Y70.34%
EPS Next 3Y56.46%
5. Dividend
5.1 Amount
MYGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MYRIAD GENETICS INC
NASDAQ:MYGN (11/21/2024, 10:24:01 AM)
15.395
+0.09 (+0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.40B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 109.96 | ||
| Fwd PE | 60.99 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.79
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.3% | ||
| ROE | -20.96% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.06% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y139.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.15%
Revenue growth 3Y5.66%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y